← Back to all trials
Not Yet Recruiting
NCT05664542
Erector Spinae Block With Ropivacaine and Dexmedetomidine on Opioid Consumption After Lumar Spine Surgeries
Conditions: Postoperative Pain
Sex: All
Ages: 18 Years – 70 Years
Phase: PHASE4
Enrollment: 42
Sponsor: Security Forces Hospital
Location: Saudi Arabia
Summary
The aim of this study is to investigate the role of 0.5 micrograms/kg of dexmedetomidine with 0.2 % ropivacaine in erector spinae block in reducing opioid consumption for patients undergoing lumbar spine surgeries.
This study will help in understanding the role of adding dexmdetomidine to ropivacaine in erector spinae block in reducing opioid consumption after lumbar spine surgeries
Eligibility Criteria
Inclusion Criteria:Patients aged between 18 and 70 years, scheduled to undergo lumbar spine surgeries with an ASA score of 1 to 3 will be included in the studyExclusion Criteria:Patients who refused enrollment or later requested removal for the study, those who are unable to give informed consent and patients with either contraindications for regional anesthesia, known allergy to local anesthetics or dexmedetomidine, bleeding diathesis, use of anticoagulants or corticosteroids, inability to operate patient controlled analgesia (PCA) system, psychiatric disorders or use of psychiatric medications will not be included in the study.
Source: ClinicalTrials.gov (NCT05664542). StuddyBuddy aggregates publicly available trial information.